摘要
目的观察吉非替尼治疗化疗失败的晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法 58例患者给予吉非替尼250mg,每天1次,至出现不能耐受的不良反应后停药。观察疗效、影响疗效的因素和不良反应。结果 58例有效率为41.4%,疾病控制率为72.4%;中位生存期为7.1个月,1年生存率为36.0%;女性患者有效率为51.9%,疾病控制率为85.2%,均高于男性的32.3%和67.7%;腺癌、细支气管肺泡癌的有效率分别为50.0%和60.0%,疾病控制率为79.4%和100.0%,均高于其他类型;无吸烟史有效率为55.2%,疾病控制率为82.8%,高于有吸烟史的27.6%和62.1%。差异均有统计学意义(P<0.05)。化疗次数和ECOG评分对疗效无影响(P>0.05)。所有患者均未发生严重不良反应。结论吉非替尼对于化疗失败的晚期NSCLC疗效满意,不良反应轻,是最佳的治疗方法 。
Objective To observe the effect and adverse reaction of gefitinib in treating paitents with advanced nonsmall cell lung cancer（NSCLC） and failed in chemotherapy.Methods 58 cases were given gefitinib 250mg po once a day,and stopped if patient could not stand the adverse reaction.Observed the effect and its influence factors,as well as the adverse reactions.Results The effective rate was 41.4% ;The disease control rate was 72.4% ;The median overall time was 7.1 months;the 1-year survival rate was 36.0%.The effective rate and disease control rate of feminine patients were 51.9% and 85.2% respectively,which were higher than 32.3% and 67.7% of the male patients.The effective rate of adenocarcinoma and bronchoalveolar carcinoma were 50.0% and 60.0% respectively,while the disease control rate were 79.4% and 100.0% respectively;all the datas were higher than other types.The effective rate and disease control rate of non-somkers was 55.2% and 82.8% respectively,which were respectively higher than 27.6% and 62.1% of the smokers.All the differences above were statistically significant（P 0.05）.The numbers of chemotherapy times and ECOG score had no influence on effect（P 0.05）.All the patients hadn＇t serious adverse reaction.Canclusion Treat NSCLC that failed in chemotherapy with gefitinb has satisfactory effect,slight adverse reaction,so gefitinib is an opetimal treatment.
出处
《临床合理用药杂志》
2010年第15期21-22,共2页
Chinese Journal of Clinical Rational Drug Use
